AbbVie shares hit record high as key immunology drug set for exclusivity until 2037

AbbVie shares rose 4% to a record high on Thursday after the U.S. drugmaker said it expected no generic competition for its blockbuster immunology drug Rinvoq until 2037, a four-year extension, accord... ...